Patricia Inácio, PhD,  science writer—

A new study entitled “Inter- and Intraspecies Metabolite Exchange Promotes Virulence of Antibiotic-Resistant Staphylococcus aureus” published in Cell Host & Microbe reports antibiotic-resistant Staphylococcus aureus interacts with other species to promote their growth and virulence inside its host. This new finding is particularly important to the…

A new study entitled “Counteracting suppression of CFTR and voltage-gated K+ channels by a bacterial pathogenic factor with the natural product tannic acid” published in Elife reports on the discovery of an inhibitor for Staphylococcus aureus, the leading agent of infections in Cystic Fibrosis…

This year at the 28th Annual North American Cystic Fibrosis Conference (NACFC) in Atlanta, Vertex Pharmaceuticals Incorporated announced their ongoing efforts to treat the underlying cause of cystic fibrosis (CF) by focusing on mutations in the CFTR gene (short for cystic fibrosis transmembrane conductance receptor) through a combination of drugs.

A new study entitled “Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study” published in October issue of BMC Pulmonary Medicine suggests that self-reported exercise improves nutritional and pulmonary outcomes in adults with cystic fibrosis. Cystic Fibrosis is a life-threatening disease, characterized…

Synedgen, Inc. will present recent study results on the successful application of the company’s novel polymer PAAG for treating Cystic Fibrosis. The data is compiled in two posters entitled “PAAG decreases viscosity and Improves Transportability of Cystic Fibrosis Mucus In Situ” and “Novel Biopolymer Mucolytic PAAG Prevents and Treats Biofilms…

Data supporting a promising, new treatment for Cystic Fibrosis (CF) developed by Verona Pharma will be presented for the first time at the 28th Annual North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia on October 9-11, 2014. Verona Pharma’s key molecule, RPL554, is currently being evaluated in a…

New research out of Germany has made an important discovery that is shedding light on what causes Cystic Fibrosis patients to experience an impaired immune response with the disease. The research, recently published in the Journal of Molecular Medicine, entitled, “Decreased Expression of HLA-DQ and -DR…